Articles related to Family Medicine/General Practice

In this meta analysis of 40 eligible trials involving 35,548 participants and seven diet programs, only the Mediterranean and low-fat diet showed effectiveness in in lowering all cause and CV mortality. Notably, their preventive value increased with increasing CV risk. Diets (with number of studies) included in the meta-analysis:

In a study of patients with DM2, 75 years old and over, continuous glucose monitoring revealed that 65% had glucose level two times below range (<54 mg/dL during ≥15 consecutive minutes) between midnight and 6 a.m. Fewer than half of the patients detected the hypoglycemic episode via self-monitoring. Because hypoglycemia episodes are associated with long-term complications, continuous glucose monitoring (CGM) could be used to improve care in these patients.

From side effect to mechanism of action to patient acceptance to managing insurance hurdles, this collection of expert points from the February Endocrine Society meeting is a helpful synopsis of need-to-know items for PCPs.

Danish researchers assembled a prospective observational cohort study of 9,533 asymptomatic people aged 40 years or older with no known ischemic heart disease to define characteristics of subclinical coronary atherosclerosis associated with the development of myocardial infarction. The study’s findings are startling.

Getting a handle on the biochemical processes that govern how food is broken down and used within the body can be a daunting task for many, and even for those who understand it, monitoring with technology isn’t always possible. This is where Levels come into play. An instant metabolic analysis just a few hours after eating is only the beginning of the Levels experience; the app focuses on four major blood glucose levers in a gamified experience: diet, exercise, stress, and sleep. Dr. Lauren Kelley-Chew, Levels’ Head of Clinical Product, discusses all of this and more.

The study was conducted while GLP-1 RAs and SGLT-2 inhibitors were still considered second-line therapies; however, in a 2022 Consensus Report, the American Diabetes Association and the European Association for the Study of Diabetes recommended these medications as first-line therapy for people with type 2 diabetes who have or are at high risk of certain complications such as heart failure, CKD, and atherosclerotic cardiovascular disease (ASCVD). Are the medications’ price tag keeping people away?